Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.450.1%
QQQ
717.500.2%
BTC/USD
79245.001.3619%
DIA
532.880.22%
GLD
406.530.06%
TLT
82.240.04%

Orchestra BioMed Holdings Inc

OBIONASDAQ
Trade with Public
Trade with Public
$5.08
0.347.17%
At close: Sep 4, 5:00 PM EST
$5.08
N/A
After Hours: Sep 4, 4:00 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Orchestra BioMed Hldgs Analyst Price Targets

Wall Street analyst price targets and consensus rating for Orchestra BioMed Hldgs (OBIO).

Price Target Range — 11 Quarters

Analyst Consensus — 8 Analysts

7Buy
1Hold
Consensus RatingBuy# Analysts8Avg. Consensus PT$13Upside to Avg. PT+158.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 11, 2026Piper SandlerMatt O'BrienPT RaiseOverweight$9→$10
May 19, 2026B. Riley SecuritiesKyle BauserPT CutBuy$12→$10
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Piper Sandler Reiterates Overweight on Orchestra BioMed Hldgs, Raises Price Target to $10

Piper Sandler analyst Matt O'Brien reiterates Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Overweight and raises the price target from $9 to $10.
Benzinga Newsdesk

PRO
B. Riley Securities Maintains Buy on Orchestra BioMed Hldgs, Lowers Price Target to $10

B. Riley Securities analyst Kyle Bauser maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy and lowers the price target from $12 to $10.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Orchestra BioMed Hldgs, Maintains $10 Price Target

HC Wainwright & Co. analyst Yi Chen reiterates Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy and maintains $10 price target.
Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Orchestra BioMed Hldgs, Raises Price Target to $13

Barclays analyst Matt Miksic maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Overweight and raises the price target from $12 to $13.
Benzinga Newsdesk

Assessing Orchestra BioMed Hldgs: Insights From 4 Financial Analysts

Benzinga Insights

PRO
Barclays Maintains Overweight on Orchestra BioMed Hldgs, Raises Price Target to $12

Barclays analyst Matt Miksic maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Overweight and raises the price target from $11 to $12.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved